Fig. 4

Copy number gain contributed to UBE2D1 overexpression and was associated with the high IL-6 level. a The relative genomic level of UBE2D1 were determined by real-time PCR in HCC and paired adjacent nontumor tissues in HCC Cohort (n = 108). LINE-1 was used as internal control. b Correlation between change on expression levels and genomic levels of UBE2D1. x, the relative UBE2D1 genomic DNA content in HCC compared with nontumor tissues, LINE-1 as an internal control. y, the relative expression level of UBE2D1 in HCC compared with nontumor tissues, β-actin as an internal control. c Relative genomic level of UBE2D1 in normal (n = 41) and hepatitis liver tissues (n = 22) compared with in HCC tissues. d The genomic level of UBE2D1 in HCC tissues and adjacent nontumor tissues from female and male HCC patients. eThe genomic content of UBE2D1 in HCC patients (n = 64, from the same set of HCC cohort) with high serum IL-6 and low serum IL-6. y, the relative genomic level of UBE2D1 in HCC compared with nontumor tissues. x, the median intensity was used as the cutoff for low and high group. f Genomic levels of UBE2D1 were detected by real-time PCR after continuous IL-6 stimulation in SMMC-7721 cells for more than 4 months. NTC, the negative control cells which was treated with equal amount of pure water(solvent of IL-6). **p < 0.01, ***p < 0.001